eurofins | Biomnis

Oncomedics
CliniSciences Group



CE
IVD

Metastatic Colorectal cancer Oncogramme® performed by Eurofins Biomnis


Oncomedics is a biotechnology company specialized in the individualisation of cancer treatments: it develops diagnosis tools to enable practitioners (surgeons, pathologists and oncologists) to personalise anti-cancer treatement, thereby considerably increasing their efficacy. The company was founded in 2006, and since 2022, has been part of Clinisciences Group, a French manufacturer and distributor of products for biological research and diagnostics.

The Oncogramme®
for metastatic colorectal cancer
1 patient - 1 tumor - 1 Oncogramme® - 1 treatment

Even today, chemotherapy treatments are administered according to protocols produced on the basis of studies that establish the efficacy of a treatment on a large, heterogeneous cohort of patients, and by choosing the most effective regardless of individual characteristics, as such, the sole effect of more than 50%[(1)] of chemotherapy treatments administered is to weaken patients, causing serious side effects without treating their cancer. Increasing the precision and efficacy of chemotherapy treatments in order to improve patient care, and thus reduce undesirable effects and associated costs, has become a major health issue.

(1) Maeda, H.; Khatami, M. Analyses of Repeated Failures in Cancer Therapy for Solid Tumors: Poor Tumor-selective Drug Delivery, Low Therapeutic Efficacy and Unsustainable Costs. Clin. Transl. Med. 2018, 7 (1). https://doi.org/10.1186/s40169-018-0185-6.

The Oncogramme®, toward a personalised medicine for cancer patients.



The Oncogramme® is a theranostic test combining therapeutic and diagnostic approaches to predict **the activity of a therapeutic molecule on a cancer patient's tumor.** Strandard of care treatement are actually tested on a sample of the tumor in an approach very similar to the antibiogram, which evaluates the efficacy of antibiotics on bacteria collected from a patient.

Responses of the patient's own cells obtained through the Oncogramme® thus assist medical practitioners in personalising the treatment:

- By identifying the additivity of anti-cancer treatments, the Oncogramme® makes it possible to identify the treatment combinations best suited to treating the patient's cancer, and also to rank their potential therapeutic treat.
- By favouring treatements that demonstrate a high level of anti-cancer activity while avoiding inefficient ones. Results obtained by Oncomedics on metastatic colorectal cancer indicate a minimal +34% increase **(84% compared to 22-48% for currently employed consensus regimens[(2)])** in response chances for first-line treatment thanks to the Oncogramme®!

Since 2016, patients with stage IV colorectal cancer have been able to benefit from the Oncogramme®: a unique solution to personalise chemotherapy.

In December 2019, Oncomedics received a favorable policy decision from the French National Authority for Health (HAS) via the "Forfait Innovation" for the derogatory reimbursement of the Oncogramme®.

Our current clinical studies, NCT03133273 (Inclusion achieved)and NCT05299840 (Ongoing inclusion), will also shed light on the impact of the Oncogramme for mCRC on Overall Survival, Relapse Free Survival and Quality of Life.

The Oncogramme® for metastatic colorectal cancer (Folfiri, Folfox, and 5FU+Folinic acid) which is CE-IVD marked, is the first indication available.

A technology already recognised in North America.

Chemosensitivity and resistance assays (CSRAS) have been widely used in North America for several decades. They have gained notable recognition from the scientific community (functional testing overcomes the limitations of genome-based precision medicine[(3)]) and, more impressively, from anticancer centers (93% of members of the National Comprehensive Cancer Network use one of these tests against gynecological cancers[(4)]).

They have displayed a significant patient's response prediction efficiency depending on the pathology[(5)]. Thanks to this choice assistance for first-lines therapies, improvement in patient's overall survival and relapse-free survival were demonstrated[(6) (7) (8)]. For the healthcare system, cost saving is validated[(9)]. With a competitive technology compared to US tests, Oncomedics offers hopeful success in cancer cure for European patients.

(2) Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. Bounaix Morand du Puch et al., J Transl Med. 2016 Jan 12;14(1):10

(3) Precision medicine for cancer with next-generation functional diagnostics. Friedman et al., Nat Rev Cancer. 2015 Dec;15(12):747-56.

(4) Cures vs. profits: Successes in translational research. Lyons-Weiler, World Scientific, 2016, ISBN:978-9814730143, p. 175.

(5) Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept. Morand du Puch CB et al., Theranostics . 2021 Sep 21;11(19):9538-9556.

(6) Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. Bosserman et al., PLoS One. 2015 May 29;10(5):e0122609.

(7) The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Bosserman et al., Cancer Res. 2012 Aug 15;72(16):3901-5.

(8) Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Herzog et al., Am J Obstet Gynecol. 2010 Jul;203(1):68.e1-6.

(9) The Value of Personalized Treatment (Rx) Planning (PTP): Cost Savings (sav) by the MiCK assay, Evidence from a Large American Self-insured Company. Latimer et al. ASCO communication 2009.

eurofins | Biomnis

Oncomedics CliniSciences Group

The Oncogramme®

A major innovation for personalized medicine


The Oncogramme® is broken down into 7 steps that are completely controlled and standardized [2] [10] [11] [12]

DAY 0

SURGERY: BIOPSY OR EXCISION

PATHOLOGISTS

TUMOR SAMPLE FOR ONCOGRAMME®



Patient tumor



TRANSPORT OF SAMPLE TO LABORATORY

In a proprietary medium, ***OncoMiD-Via:*** *preserves viability of sample cells at 4°C for 48 hours*






OncoMiD-Diss: *maintains high cell viability (> 80%) at start of culture and makes it possible to obtain ≥ 95% cultures devoid of contamination*

DISSOCIATION AND CULTURE OF SAMPLES

in Oncomedics' central laboratory or in licensed laboratories:
• Lowering micro-environment contamination
• Improving growth of tumor subpopulation



Culture of tumor cells using a selective medium with a tightly controlled formulation, ***OncoMiD:*** *purifies cell population (cancer cell enrichment) to obtain relevant analyses in 97% cases*



CELL DEATH / ANALYSIS

Double fluorescent coloration that unambiguously distinguishes between live and dead cells



Automated cell counting using a slide scanner.
Proprietary image processing and analysis algorithm.


RESULTS AND REPORT

Standardized response profile for each patient: predicts the sensitivity of a metastatic colorectal patient to a chemotherapy treatment with a success rate of 84%



DAY 15

Example of Research Use Only Oncogramme® for metastatic colorectal cancer



CE-IVD Oncogramme®: Folfiri, Folfox, and 5FU+Folinic acid

(10) Oncogramme, a new individualized tumor response testing method: application to colon cancer. Loum et al., Cytotechnology 2010 Oct;62(5):381-8.
(11) Morand du Puch, C. B.; Vanderstraete, M.; Giraud, S.; Lautrette, C.; Christou, N.; Mathonnet, M. Benefits of Functional Assays in Personalized Cancer Medicine: More than Just a Proof-of-Concept. Theranostics 2021, 11 (19), 9538–9556. https://doi.org/10.7150/thno.55954.
(12) ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme®. Mathonnet M et al.,Trials. 2021 Aug 21;22(1):556. doi: 10.1186/s13063-021-05531-y.

The Oncogramme® puts the patient at the very center of his cure for individual and societal benefits

MEDICAL STAFF

- Optimize decision-making process
- Test of drug efficiency alone or in combination
- Offer a targeted therapy to all patients, including those only eligible to chemotherapy

HEALTH SERVICES

- Reduce treatment costs by a minimum of 22%
- Save time to better cure patients.
- Clinical study [12]

PATIENT CURE

- Minimal 34% increase in chances to respond to first-line treatment
- Reduce useless negative side
- effects due to first-line treatment failure

eurofins | Biomnis

Oncomedics
CliniSciences Group

17/19 avenue Tony Garnier
BP 7322 - 69357 LYON Cedex 07 - FRANCE
Tel: +33 4 72 80 23 85
international@biomnis.eurofinseu.com
www.eurofins-biomnis.com

5 Rue de Gémini, 87280 Limoges - France
Tel: +33 5 55 33 85 25
info@oncomedics.com
www.oncomedics.com

cliniSciences

Austria
Company: CliniSciecnes GmbH

Belgium
Company: CliniSciences S.R.L

Denmark
Company: CliniSciences ApS

Finland
Company: CliniSciences ApS

France
Company: CliniSciences S.A.S

Germany
Company: Biotrend Chemikalien GmbH

Iceland
Company: CliniSciences ApS

Ireland
Company: CliniSciences Limited

Italy
Company: CliniSciences S.r.I

Netherlands
Company: CliniSciences B.V.

Norway
Company: CliniSciences

Poland
Company: CliniSciences sp.Z.o.o.

Portugal
Company: Quimigen Unipessoal LDA

Spain
Company: CliniSciences Lab Solutions

Sweden
Company: CliniSciences ApS

Switzertand
Company: CliniSciences Limited

UK
Company: CliniSciences Limited

USA
Company:CkiniSciences LLC

version of 22-10-2025